Skip to main content
OpenTrials
Completed

NCT Number: NCT05941832

ANNE Sensor Monitoring in Cystic Fibrosis

The ANNE sensor is a small, wire free device that is placed on the chest with a removable adhesive patch. It measures things like temperature, heart rate and breathing rate without the need for wires and large machines that are needed currently. The aim is to trial this sensor in a small group of participants to see how well it is tolerated and how well it measures. The aim is to see if the sensor could provide additional information to help the medical team detect when a participant is becoming unwell with less need for the participant to perform repeated tests.

Participants will wear the sensor for 6 weeks continuously (apart from when it is charged for 4-6 hours each day). Participants can perform their usual activities whilst wearing the sensor but should not submerse the sensor in water for long periods of time.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal Papworth Hospital

Cambridge, Cambridgeshire, CB2 0AA, United Kingdom

About this study

Rationale

The aim of this study is to explore the potential use of the ANNE Chest Sensor to assist or improve the detection of health conditions in people with CF. The emphasis is on identifying onset and progression of pulmonary exacerbations.

The ANNE Chest Sensor is now being applied to help people with respiratory and other conditions. Through advanced analytics and signal processing, the device includes an accelerometer, temperature sensor and electrocardiogram, from which vital signs such as respiratory rate, skin and body temperature, ECG, heart rate, step count, fall count and body position can be measured.

Royal Papworth Hospital has demonstrated that daily recordings of a range of physiological parameters (e.g., spirometry, pulse oximetry, activity, heart rate, etc.) in combination with self-reported survey responses (e.g., general wellness, cough, sleep quality) in people with CF holds promise to more accurately track fluctuations in health condition(s), in particular the start of pulmonary exacerbations (PE). This data is collected remotely at the study participant's home using remote/virtual online tools, as part of a larger effort to take a more virtual approach to clinics. Passive and continuous collection of a patient's data for early detection is a natural extension of this approach.

Study Design

This is a 6-month single-centre observational, prospective study, designed as a pilot study. We aim to recruit 10 adult patients with Cystic Fibrosis (CF) who are already participating in the Project Breathe home monitoring project at Royal Papworth Hospital. Participants will be enrolled for 6 weeks.

This study is designed to run as a non-disruptive study with no impact on routine clinical care and the sensor data will have no influence on treatment decisions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Cystic Fibrosis based on genetic testing and /or sweat chloride levels.
  • At least >/= 18 years of age at time of consent
  • Able to provide written informed consent
  • Patients who are currently undertaking home monitoring / virtual clinics as part of Project Breathe

Exclusion criteria

  • Patients unable to provide written informed consent
  • Patients who are currently not undertaking home monitoring / virtual clinics as part of Project Breathe
  • Lung transplant recipients.
  • Severe skin conditions e.g. psoriasis, severe eczema
  • Patients with a pacemaker

Treatment and study plan

ANNE Chest Sensor

Device

Wearing ANNE Chest Sensor for 6 weeks

Primary outcomes

  1. Number of Participants With ANNE Sensor Related Adverse Skin Sensitivity Events

    Time frame: 6 weeks

    Number of ANNE sensor related Adverse Events reported during the study

Secondary outcomes

  1. Difference in Heart Rate (bpm) Measured by The ANNE Chest Sensor vs Current Heart Rate Home Monitoring

    Time frame: 6 weeks

    Number of beats per minute (bpm) measured by the ANNE Chest Sensor vs current home heart rate monitoring (bpm)

  2. Difference in Oxygen Levels (%) Measured by The Anne Chest Sensor vs Current Oxygen Levels Home Measurements

    Time frame: 6 weeks

    Blood oxygen levels (%) measured by the ANNE Chest Sensor vs current home oxygen level monitoring (%)

  3. Difference in Activity (kcal) Measured by The ANNE Chest Sensor vs Current Home Activity Monitoring

    Time frame: 6 weeks

    Kcal expended through exercise as measured by the ANNE Chest Sensor vs current home monitoring of activity (kcal)

Sponsors and collaborators

Lead sponsor

Papworth Hospital NHS Foundation Trust

Other Gov

Collaborators

  • Cystic Fibrosis Trust
  • LifeArc

Registry information

Official study title

ASM in CF:ANNE Sensor Monitoring in Cystic Fibrosis

Acronym: ASM in CF

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 12, 2023
Registry last updated
May 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.